Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2021 | $139.00 → $155.00 | Buy | Needham |
| 11/17/2021 | $146.00 → $132.00 | Overweight | Keybanc |
| 11/11/2021 | $100.00 → $120.00 | Neutral | Citigroup |
| 11/10/2021 | $121.00 → $139.00 | Buy | Needham |
| 9/7/2021 | $115.00 → $146.00 | Overweight | Keybanc |
| 8/6/2021 | $130.00 → $114.00 | Buy | Needham |
Needham reiterated coverage of Brooks Automation with a rating of Buy and set a new price target of $155.00 from $139.00 previously
Keybanc reiterated coverage of Brooks Automation with a rating of Overweight and set a new price target of $132.00 from $146.00 previously
Citigroup reiterated coverage of Brooks Automation with a rating of Neutral and set a new price target of $120.00 from $100.00 previously
SC 13G - Brooks Automation, Inc. (0000933974) (Subject)
SC 13G/A - Brooks Automation, Inc. (0000933974) (Subject)
8-K - Azenta, Inc. (0000933974) (Filer)
10-K - Brooks Automation, Inc. (0000933974) (Filer)
8-K - Brooks Automation, Inc. (0000933974) (Filer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
4 - Brooks Automation, Inc. (0000933974) (Issuer)
Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or the "Company") announced today that it has completed its previously announced corporate name change from "Brooks Automation, Inc." to "Azenta, Inc." In conjunction with the corporate name change, the Company will begin trading on the Nasdaq Global Select Market under the new ticker symbol, AZTA, effective at the open of market trading on December 1, 2021. This change follows the launch of the Company's life sciences brand, Azenta Life Sciences and the Investor Day held on November 16, 2021. The Company anticipates completion of the sale of the semiconductor automation business in the first half of calendar year 2022, at which time the Company will bec
CHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:3
CHELMSFORD, Mass., Aug. 9, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the third quarter ended June 30, 2022. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2022 2022 2021 Prior Qtr. Prior Yr. Revenue from Continuing Operations $ 133 $ 146 $ 129 (9) % 3 % Life Sciences Products $ 47 $ 54 $ 49 (12) % (3) % Life Sciences Services $ 85 $ 92 $ 80 (7) % 6 % Diluted EPS Continuing Operations $ (0.09) $ (0.02) $ (0.02) nm nm Diluted EPS Total $ (0.13) $ 28.28 $ 0.53 nm nm Non-GAAP Diluted EPS Continuing Operations $ 0.12 $ 0.12 $ 0.10 0 % 14 % Adjusted EBITDA Continuing Operations $ 14 $ 19 $ 19 (29) % (26) % M
Enhances Azenta's Leadership Position in Cold Chain Solutions and End-to-End Sample Management CHELMSFORD, Mass., Aug. 8, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments across the globe. The cash purchase price to be paid at closing will be approximately €410 million. Additional cash consideration, up to €50 million, may be paid upon achievement of certain future performance milestones. The transaction is expected to close in O
CHELMSFORD, Mass., Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes. The Company will host a conference call and live webcast to discuss its financial results on the same day, Monday, November 14, 2022 at 4:30 p.m. Eastern Time. To participate in the conference call, please dial 800-936-4761 for domestic callers and +1-212-231-2922 for international callers. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:3
CHELMSFORD, Mass., Oct. 3, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has closed its previously announced acquisition of B Medical Systems S.á r.l and its subsidiaries ("B Medical"), a market leader in temperature-controlled storage and transportation solutions that enables the delivery of life-saving treatments to more than 150 countries worldwide. This acquisition complements Azenta's cold chain capabilities, adding differentiated solutions for reliable and traceable transport of temperature-sensitive specimens. B Medical, headquartered in Hosingen, Luxembourg, is one of the leading vaccine cold chain providers serving primarily fast-growing emerging markets, w
CHELMSFORD, Mass., Sept. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in the Baird 2022 Global Healthcare Conference in New York City, on Wednesday, September 14, 2022, which includes a presentation beginning at 9:40 am ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain
CHELMSFORD, Mass., Jan. 6, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that it has appointed Matthew McManus Chief Operating Officer effective January 17th. In this newly created role, Dr. McManus will oversee Life Sciences Products, Services, and all commercial operations of the business and will report directly to the CEO. "We are excited to have Matt join the Company as our COO," said Steve Schwartz, President and CEO of Azenta. "Matt brings decades of expertise in life sciences. His depth of knowledge and valuable perspective will enhance our leadership position in the markets we serve." Dr. McManus joins Azenta with over 25 years of experience in the life s